Results 51 to 60 of about 6,842,005 (300)
Endpoints in respiratory diseases [PDF]
A wide range of outcome measures or endpoints has been used in clinical trials to assess the effects of treatments in paediatric respiratory diseases. This can make it difficult to compare treatment outcomes from different trials and also to understand whether new treatments offer a real clinical benefit for patients.
DE BENEDICTIS FM +3 more
openaire +4 more sources
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura +19 more
wiley +1 more source
Respiratory Disease and Infection [PDF]
Medicine is an ever-changing science. Every day we are encountered with the new developments and knowledge in the pathogenesis, mechanism of disease, newer diagnostic modalities, treatment options and new challenges in the management of the various ...
core +2 more sources
Obesity and respiratory diseases
The obesity epidemic is a global problem, which is set to increase over time. However, the effects of obesity on the respiratory system are often underappreciated. In this review, we will discuss the mechanical effects of obesity on lung physiology and the function of adipose tissue as an endocrine organ producing systemic inflammation and effecting ...
Zammit,Christopher +3 more
openaire +5 more sources
LUNAR is a liver‐specific long noncoding RNA (lncRNA) that is highly expressed in normal liver but becomes epigenetically silenced in hepatocellular carcinoma through promoter hypermethylation. Loss of LUNAR is associated with NOTCH activation, epithelial–mesenchymal transition, and metastasis, whereas restoring LUNAR restrains metastatic progression ...
Se Ha Jang +9 more
wiley +1 more source
Observing Huntington's disease: the European Huntington's Disease Network's REGISTRY. [PDF]
The unparalleled collection of clinical data and biomaterials within the EHDN's REGISTRY can expedite the search for disease modifiers (genetic and environmental) of age at onset and disease progression that could be harnessed for the development of ...
Handley, Olivia J +59 more
core +1 more source
PANoptosis in the pathogenesis of myelodysplastic syndromes
PANoptosis, a combination of three types of programmed cell death, is mediated by a large protein complex called a PANoptosome. In healthy bone marrow hematopoietic cells, PANoptosis is restricted by inhibitory signaling. In MDS, bone marrow cells become sensitive to the PANoptotic stimuli due to the aberrant inactivation of inhibitory signaling or ...
Rohit Thalla +4 more
wiley +1 more source
Respiratory medication use in Australia 2003–2013: treatment of asthma and COPD [PDF]
This report describes patterns of dispensing of respiratory medications in Australia through detailed analyses of Pharmaceutical Benefits Scheme data, as well as other sources, to draw inferences about respiratory medication use among patients with ...
Leanne Poulos +4 more
core
Incidence and risk factors for respiratory syncytial virus and human metapneumovirus infections among children in the remote highlands of Peru [PDF]
The disease burden and risk factors for respiratory syncytial virus (RSV) and human metapneumovirus (MPV) infections among children living in remote, rural areas remain unclear.; We conducted a prospective, household-based cohort study of children aged ...
Gil, Ana I. +48 more
core +2 more sources
The biochemical characterisation of respiratory mucus & mucins in normal, asthma & COPD [PDF]
Includes abstract.Includes bibliographical references (leaves 78-87).Airway mucus hyper-secretion is the main cause of mortality and morbidity in respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) and is the leading ...
Trimmel, Astrid Joan
core +1 more source

